The inherited retinal disease (IRD) community is abuzz with promising developments in the treatment of Retinitis Pigmentosa (RP), a group of rare genetic eye diseases that lead to progressive vision loss. Recent advancements, particularly in gene therapy, are offering new hope for patients and families, moving beyond single-gene specific treatments to potentially address a wider range of genetic mutations.
Understanding Retinitis Pigmentosa and the Need for Innovation
Retinitis Pigmentosa affects an estimated 1.5 million people globally, causing light-detecting cells in the retina to break down over time, leading to vision loss. This condition typically begins with night blindness and can progress to loss of peripheral, color, and central vision. More than 60 different genes can contribute to RP, making genetic testing crucial for identifying the underlying mutation and determining eligibility for specific treatments or clinical trials.
While Luxturna (voretigene neparvovec) was the first FDA-approved gene therapy for RP, it is specific to mutations in both copies of the RPE65 gene, which accounts for a small fraction (0.3% to 1%) of all RP cases. This highlights the significant need for therapies that can benefit a broader patient population.
Promising New Gene Therapies on the Horizon
Several companies are developing innovative gene therapies that aim to address RP more broadly:
- Optogenetic Therapies (e.g., MCO-010): This approach, being explored by companies like Nanoscope Therapeutics, uses optogenetics to activate retinal cells that survive after photoreceptor cells are lost. The therapy, delivered via a one-time intravitreal injection, introduces light-sensing molecules to these surviving cells, enabling them to function as new light-sensing cells. MCO-010 is considered